Infection prevention and control

Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example

Shiri, T.; Evans, M.; Talarico, C. A.; Morgan, A. R.; Mussad, M.; Buck, P. O.; McEwan, P.; Strain, W. D. (MDPI, 2021-10-15)

Debate persists around the risk-benefit balance of vaccinating adolescents and children against COVID-19. Central to this debate is quantifying the contribution of adolescents and children to the transmission of SARS-CoV-2, ...

The role of an infection prevention and control nurse

West, J. (International Centre for Eye Health, 2021-06-25)

Impact of COVID-19 and other infectious conditions requiring isolation on the provision of and adaptations to fundamental nursing care in hospital in terms of overall patient experience, care quality, functional ability, and treatment outcomes: systematic review

Whear, R.; Abbott, R. A.; Bethel, A.; Richards, D. A.; Garside, R.; Cockcroft, E.; Iles-Smith, H.; Logan, P. A.; Rafferty, A. M.; Shepherd, M.; Sugg, H. V. R.; Russell, A. M.; Cruickshank, S.; Tooze, S.; Melendez-Torres, G. J.; Thompson Coon, J. (Wiley, 2021-08-23)

AIM: This systematic review identifies, appraises and synthesizes the evidence on the provision of fundamental nursing care to hospitalized patients with a highly infectious virus and the effectiveness of adaptations to ...

Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019-2020 Season

Strain, William David; Mansi, James; Boikos, Constantina; Boivin, Michael; Fisher, William A. (MDPI, 2021-03-26)

Older adults (≥65 years) are at elevated risk of influenza-related morbidity and mortality. Many developed countries do not achieve the World Health Organization influenza immunization target of 75% in people ≥65 years. ...

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Heath, P. T.; Galiza, E. P.; Baxter, D. N.; Boffito, M.; Browne, D.; Burns, F.; Chadwick, D. R.; Clark, R.; Cosgrove, C.; Galloway, J.; Goodman, A. L.; Heer, A.; Higham, A.; Iyengar, S.; Jamal, A.; Jeanes, C.; Kalra, P. A.; Kyriakidou, C.; McAuley, D. F.; Meyrick, A.; Minassian, A. M.; Minton, J.; Moore, P.; Munsoor, I.; Nicholls, H.; Osanlou, O.; Packham, J.; Pretswell, C. H.; San Francisco Ramos, A.; Saralaya, D.; Sheridan, R. P.; Smith, R.; Soiza, R. L.; Swift, P. A.; Thomson, E. C.; Turner, J.; Viljoen, M. E.; Albert, G.; Cho, I.; Dubovsky, F.; Glenn, G.; Rivers, J.; Robertson, A.; Smith, K.; Toback, S. (Massachusetts Medical Society, 2021-06-30)

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike ...